Search

Your search keyword '"Carreras, Enric"' showing total 390 results

Search Constraints

Start Over You searched for: Author "Carreras, Enric" Remove constraint Author: "Carreras, Enric" Language english Remove constraint Language: english
390 results on '"Carreras, Enric"'

Search Results

1. Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activation

2. EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation

6. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT)

7. Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis

11. Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant

12. Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry

13. Hyponatremia induced by post-transplant cyclophosphamide in allogeneic hematopoietic cell transplantation

14. Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era

17. An endothelial proinflammatory phenotype precedes the development of the engraftment syndrome after autologous Hct

18. Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide based prophylaxis.

19. Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation

20. Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation

21. Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations

23. Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?

25. The EBMT Handbook

26. Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party

28. Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.

31. Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis

32. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group

33. Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells

34. Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes

35. Bacterial Bloodstream Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

37. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT

38. Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy

40. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis

43. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation

47. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico

50. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation

Catalog

Books, media, physical & digital resources